Therapeutic results of the GIMEMA 0496 trial according to the 3 genotypic subgroups
. | . | 1 . | 2 . | . | 3 . | . |
|---|---|---|---|---|---|---|
| Therapeutic response . | Total no. of patients (%), n = 62 . | ALL1/AF4-positive (%), n = 23 . | ALL1/AF4-BCR/ABL-negative (%), n = 33 . | P, 1 vs 2 . | BCR/ABL-positive (%), n = 6 . | P, 1 vs 2 vs 3 . |
| CR | 52 (84) | 21 (91) | 28 (85) | 3 (50) | ||
| Resistant | 4 (6) | 0 (0) | 3 (9) | NS | 1 (17) | NS |
| DI | 6 (10) | 2 (9) | 2 (6) | 2 (33) | ||
| Relapses | .003 | .003 | ||||
| Yes | 31 (60) | 17 (81) | 11 (39) | 3 (100) | ||
| No | 21 (40) | 4 (19) | 17 (61) | 0 (0) | ||
| Deaths | .01 | .002 | ||||
| Yes | 36 (58) | 17 (74) | 13 (39) | 6 (100) | ||
| No | 26 (42) | 6 (26) | 20 (61) | 0 (0) |
. | . | 1 . | 2 . | . | 3 . | . |
|---|---|---|---|---|---|---|
| Therapeutic response . | Total no. of patients (%), n = 62 . | ALL1/AF4-positive (%), n = 23 . | ALL1/AF4-BCR/ABL-negative (%), n = 33 . | P, 1 vs 2 . | BCR/ABL-positive (%), n = 6 . | P, 1 vs 2 vs 3 . |
| CR | 52 (84) | 21 (91) | 28 (85) | 3 (50) | ||
| Resistant | 4 (6) | 0 (0) | 3 (9) | NS | 1 (17) | NS |
| DI | 6 (10) | 2 (9) | 2 (6) | 2 (33) | ||
| Relapses | .003 | .003 | ||||
| Yes | 31 (60) | 17 (81) | 11 (39) | 3 (100) | ||
| No | 21 (40) | 4 (19) | 17 (61) | 0 (0) | ||
| Deaths | .01 | .002 | ||||
| Yes | 36 (58) | 17 (74) | 13 (39) | 6 (100) | ||
| No | 26 (42) | 6 (26) | 20 (61) | 0 (0) |
DI indicates deaths during induction treatment.